drugset / Trial / NCT00144482

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

NCT00144482

Phase 3 Completed 122 enrolled Chugai Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the effectiveness and safety in randomized, double-blind, parallel-group study in anemic cancer patients undergoing chemotherapy

Timeline

Start
2003-12
Primary completion
2005-03
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 36000 iu Subcutaneous